Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

AbbVie Gains License Option to Cugene’s Autoimmune and Inflammatory Disease Portfolio

AbbVie Gains License Option to Cugene’s Autoimmune and Inflammatory Disease Portfolio

AbbVie has secured options to worldwide rights for several of Cugene’s interleukin-2 (IL-2) muteins, which are proteins with altered amino acid sequences that are being evaluated as potential treatments for autoimmune and inflammatory diseases.

Cugene’s lead candidate, CUG252, is designed to selectively activate immune-suppressive Treg cells while reducing undesired IL-2 activity. CUG252 is currently in a phase 1 study in healthy volunteers.

Under the terms of the agreement, Cugene will receive an upfront payment of $48.5 million, plus additional payments for reaching developmental or regulatory milestones.

It will also receive separate payments if AbbVie exercises its licensing option for a particular mutein as well as sales-based milestones and tiered royalties.

Cugene is a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines that harness specific immune cells to treat autoimmune disease and cancer.

May 20, 2022

https://www.fdanews.com/


0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies